Phase-III trials of a vaccine made by India's Bharat Biotech showed it was 93.4 percent effective against severe symptomatic COVID-19, the firm said on Saturday, a finding that could boost people's acceptance of Covaxin.
The data demonstrated 65.2 percent protection against the Delta variant, first identified in India, that led to a surge in infections in April and May, and the world's highest daily death tolls.
India's homegrown vaccine also showed effectiveness of 77.8 percent against symptomatic COVID-19 in the trial.
Last month, vaccine maker AstraZeneca Plc also said its vaccine was effective against the Delta and Kappa variants, citing a study.
India has been administering the AstraZeneca vaccine, made domestically by the Serum Institute of India, which said last month it planned to step up monthly production from July, to nearly 100 million doses.
Bharat Biotech now estimates it will make 23 million doses a month.
The Phase-III data came as Ocugen Inc, which is co-developing Covaxin with Bharat Biotech for the U.S. market, prepares to file a request for full U.S. approval.
India, with a tally of 30.45 million infections, is the second most affected nation after the United States, with 33 million. The south Asian nation's death toll has now crossed 400,000.
Italian health workers lodge legal challenge against vaccine obligationThree hundred healthcare workers in Italy have lodged a legal challenge against the requirement that they get vaccinated against coronavirus, ... Coronavirus
Brazil’s Bolsonaro faces probe for alleged COVID-19 vaccine negligenceBrazil’s prosecutor general office has requested the country’s top court to investigate President Jair Bolsonaro for possible negligence in the ... Coronavirus
Johnson & Johnson says COVID-19 vaccine shows strong promise against Delta variantJohnson & Johnson said late Thursday that its single-shot COVID-19 vaccine showed strong promise against the Delta variant and other emerging strains ... Coronavirus
Two doses of COVID-19 vaccine seems to protect against Delta variant: European AgencyTwo doses of Covid vaccine appear to provide protection against the rapidly spreading Delta variant of the coronavirus, the European Medicines Agency ... Coronavirus